1. In Vivo
  2. >>Growth

Commercializing Rare Disease Therapies Is Getting Tougher

 
• By Jane Barlow, Roger Longman, and Rob O'Brien

For an industry increasingly dominated by these drugs, commercial programs need to take on the risk once reserved for development.  

Things are getting tougher
Rare disease therapies are becoming more difficult to commercialize • Source: Shutterstock

Historically, if you were to pick a symbolic hero of the drug industry’s rise to prominence it might be Alexander Fleming, who discovered penicillin; Jonas Salk, who developed the polio vaccine; or maybe the Nobel prize winners James Black, who developed the first beta-blocker and H2 antagonist; or Gertrude Elion, who catalyzed the development of antivirals. Their discoveries, after all, resulted in medicines that successfully treated millions of heretofore untreatable patients.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Growth

Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Eleanor Malone

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Financing Quarterly Statistics, Q1 2025

 
• By Maureen Riordan and Deanna Kamienski

During Q1, biopharmas brought in an aggregate $13.1bn in financing and device company fundraising totaled $5bn; while in vitro diagnostic firms and research tools players raised $418m.

Deals In Depth: March 2025

 
• By Maureen Riordan

Eight $1bn+ alliances were penned in March, and five exceeded $2bn.

Three Steps To Investor Heaven For Founders: Articulate, Explain, Clarify

 
• By Ashley Yeo

Capital remains available for good healthtech projects, but it is more concentrated and harder to find than of late. Founders and inventors must know how to unlock it. The BioWales 2025 investor panel told them where they could be going wrong.

More from In Vivo

Podcast: Ochre Bio’s Approach To Precision Medicine In Liver Treatment

 
• By David Wild

Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.

Richard DiMarchi On The GLP-1 Revolution: An Overnight Success After 40 Years

 
• By Andrew Warmington

As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.

Rising Leaders 2025: João Ribas On Building At The Intersection Of Science And Business

 
• By Jo Shorthouse

João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.